Buy Noliprel a (Indapamide, Perindopril) 0,625 mg + 2,5 mg

Noliprel a (Indapamide, Perindopril) 0,625 mg + 2,5 mg

Description

Features

Reviews

Instructions for Noliprel a (Indapamide, Perindopril) 0,625 mg + 2,5 mg

English product name
Noliprel® A

Release form
tabbed film coating, 0.625 mg+2.5 mg: 14, 29, 30 or 90 pcs
tabbed film coating, 0.625 mg+2.5 mg: 14, 30 or 90 pcs

Description:

The tablets are covered with film sheath, white in color, oblong, with risk on both sides.

1 tab.
indapamide 0.625 mg
perindoprila arginine 2.5 mg,
which corresponds to perindopriva content 1.6975 mg
Auxiliary substances: lactose monohydrate, magnesium stearate, maltodextrin, silicon dioxide colloidal anhydrous, carboxymethyl sodium starch (type A).

Film sheath composition: macrogol 6000, premix for the white film shell SEPIFILM 37781 RBC (glycerol, hypromellose, macrogol 6000, magnesium stearate, titanium dioxide (E171)).

14 pcs. - polypropylene bottles with a dosator and a stopper containing a moisture-absorbing gel (1) - cardboard packs with the control of the first opening.
29 pcs. - polypropylene bottles with a dosator and a stopper containing a moisture-absorbing gel (1) - cardboard packs with the control of the first opening.
30 pcs - polypropylene bottles with a dosator and a stopper containing a moisture-absorbing gel (1) - cardboard packs with the control of the first opening.

Packages for stationary:
30 pcs - polypropylene bottles with a dosator and a stopper containing a moisture-absorbing gel (3) - cardboard packs with the control of the first opening.

ATC codes
C09BA04 Perindopril in combination with diuretics

Clinical-pharmacological groups / Group affiliation
Hypotensive combination drug (ACE inhibitor and diuretic)

Active substance Noliprel a
indapamide
perindopril (in the form of arginine perindopril)

Pharmacotherapy group Noliprel a
Hypotensive combined agent (diuretic+ACE inhibitor)

Best before date
The shelf life is three years. Do not apply after the expiry date indicated on the package.

English product name
Noliprel® A

Release form Noliprel a
tabbed film coating, 0.625 mg+2.5 mg: 14, 29, 30 or 90 pcs
tabbed film coating, 0.625 mg+2.5 mg: 14, 30 or 90 pcs
Description
The tablets are covered with film sheath, white in color, oblong, with risk on both sides.

Film sheath composition: macrogol 6000, premix for the white film shell SEPIFILM 37781 RBC (glycerol, hypromellose, macrogol 6000, magnesium stearate, titanium dioxide (E171)).

Packages for stationary:
30 pcs - polypropylene bottles with a dosator and a stopper containing a moisture-absorbing gel (3) - cardboard packs with the control of the first opening.

ATC codes
C09BA04 Perindopril in combination with diuretics

Clinical-pharmacological groups / Group affiliation
Hypotensive combination drug (ACE inhibitor and diuretic)

Active substance
indapamide
perindopril (in the form of arginine perindopril)

Pharmacotherapy group
Hypotensive combined agent (diuretic+ACE inhibitor)

Best before date
The shelf life is three years. Do not apply after the expiry date indicated on the package.

Testimony Noliprel a:

essential hypertension;
In patients with arterial hypertension and type 2 diabetes to reduce the risk of developing microvascular complications
(from the kidneys) and macrovascular complications from cardiovascular disease.
Method of use, course and dosage
It is used in the morning, preferably before meals.

Essential hypertension
1 tab. 1 time per day.
If possible, the administration of the preparation begins with the selection of doses of single-component drugs. In case of clinical necessity, it is possible to consider a combination therapy with Noliprel® A immediately after monotherapy.
Patients with arterial hypertension and diabetes are two types to reduce the risk of developing microvascular complications (from the kidneys) and macrovascular complications from cardiovascular disease
They are given one tab every day. After three months of therapy, if well tolerated, it is possible to increase the dose to two tab. once a day (or 1 tab. Noliprel® A forte once a day).
Elderly patients should be treated with the drug after controlling kidney function and AD.
The drug is contraindicated in patients with severe kidney dysfunction (QC<30 ml/min). In patients with moderate kidney dysfunction (QC 30-60 ml/min), it is recommended to start therapy with the necessary doses of drugs (in the form of monotherapy) included in the drug Noliprel® A. Patients with QC ≥ 60 ml/min dose correction is not required. On the background of therapy, regular monitoring of the concentration of creatinine and potassium in blood plasma is necessary.

The drug is contraindicated in patients with severe liver dysfunction. In case of moderate liver function disorder, no dose correction is required.
Noliprel® A is contraindicated in children and adolescents under the age of eighteen due to the lack of data on efficacy and safety of the drug in patients of this age group.